Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy

Journal of Immunology

Volumn 194, Issue 8, 2015, Pages 4008-4018

  Linhart, Birgit ^a   Focke Tejkl, Margarete ^a   Weber, Milena ^a   Narayanan, Meena ^a   Neubauer, Angela ^b   Mayrhofer, Hannes ^a   Blatt, Katharina ^a   Lupinek, Christian ^a   Valent, Peter ^a   Valenta, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BIOMAY AG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; EPITOPE; GRASS POLLEN EXTRACT; HYBRID PROTEIN; HYPOALLERGENIC MOSAIC PROTEIN P; HYPOALLERGENIC MOSAIC PROTEIN Q; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; PLANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BASOPHIL; CONTROLLED STUDY; CROSS REACTION; ESCHERICHIA COLI; FEMALE; GRASS POLLEN; IMMUNIZATION; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; DIRECTED MOLECULAR EVOLUTION; GENETICS; HUMAN; IMMUNOLOGY; MALE; PHLEUM PRATENSE; POLLEN; RHINITIS, ALLERGIC, SEASONAL;

ALLERGENS; ANIMALS; DIRECTED MOLECULAR EVOLUTION; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED BALB C; PHLEUM; PLANT PROTEINS; POLLEN; RECOMBINANT FUSION PROTEINS; RHINITIS, ALLERGIC, SEASONAL;

EID: 84927596377     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400402     Document Type: Article

References (37)

1. Panzner, P., M. Vachová, P. Vítovcová, P. Brodská, and T. Vlas. 2014. A comprehensive analysis of middle-European molecular sensitization profiles to pollen allergens. Int. Arch. Allergy Immunol. 164:74-82.
2. Galant, S., W. Berger, S. Gillman, A. Goldsobel, G. Incaudo, L. Kanter, S. Machtinger, A. McLean, B. Prenner, W. Sokol, et al; Allergy Skin Test Project Team. 1998. Prevalence of sensitization to aeroallergens in California patients with respiratory allergy. Ann. Allergy Asthma Immunol. 81:203-210.
3. Suphioglu, C., M. B. Singh, P. Taylor, R. Bellomo, P. Holmes, R. Puy, and R. B. Knox. 1992. Mechanism of grass-pollen-induced asthma. Lancet 339:569-572.
4. Akdis, M. 2009. Immune tolerance in allergy. Curr. Opin. Immunol. 21:700-707.
5. Durham, S. R., S. M. Walker, E. M. Varga, M. R. Jacobson, F. O'Brien, W. Noble, S. J. Till, Q. A. Hamid, and K. T. Nouri-Aria. 1999. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341:468-475.
6. Möller, C., S. Dreborg, H. A. Ferdousi, S. Halken, A. Høst, L. Jacobsen, A. Koivikko, D. Y. Koller, B. Niggemann, L. A. Norberg, et al. 2002. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109:251-256.
7. Noon, L. 1911. Prophylactic inoculation against hey fever. Lancet 177:1572-1573.
8. Winther, L., J. Arnved, H. J. Malling, H. Nolte, and H. Mosbech. 2006. Sideeffects of allergen-specific immunotherapy: a prospective multi-centre study. Clin. Exp. Allergy 36:254-260.
9. Focke, M., K. Marth, S. Flicker, and R. Valenta. 2008. Heterogeneity of commercial timothy grass pollen extracts. Clin. Exp. Allergy 38:1400-1408.
10. Mothes, N., M. Heinzkill, K. J. Drachenberg, W. R. Sperr, M. T. Krauth, Y. Majlesi, H. Semper, P. Valent, V. Niederberger, D. Kraft, and R. Valenta. 2003. Allergen-specific immunotherapy with a monophosphoryl lipid Aadjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy 33:1198-1208.
11. Marsh, D. G., L. M. Lichtenstein, and D. H. Campbell. 1970. Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology 18:705-722.
12. Thomas, W. R. 2011. The advent of recombinant allergens and allergen cloning. J. Allergy Clin. Immunol. 127:855-859.
13. Valenta, R., F. Ferreira, M. Focke-Tejkl, B. Linhart, V. Niederberger, I. Swoboda, and S. Vrtala. 2010. From allergen genes to allergy vaccines. Annu. Rev. Immunol. 28:211-241.
14. Linhart, B., and R. Valenta. 2005. Molecular design of allergy vaccines. Curr. Opin. Immunol. 17:646-655.
15. Linhart, B., and R. Valenta. 2012. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine 30:4328-4335.
16. Cromwell, O., D. Häfner, and A. Nandy. 2011. Recombinant allergens for specific immunotherapy. J. Allergy Clin. Immunol. 127:865-872.
17. Suphioglu, C. 2000. What are the important allergens in grass pollen that are linked to human allergic disease? Clin. Exp. Allergy 30:1335-1341.
18. Andersson, K., and J. Lidholm. 2003. Characteristics and immunobiology of grass pollen allergens. Int. Arch. Allergy Immunol. 130:87-107.
19. Westritschnig, K., F. Horak, I. Swoboda, N. Balic, S. Spitzauer, M. Kundi, H. Fiebig, R. Suck, O. Cromwell, and R. Valenta. 2008. Different allergenic activity of grass pollen allergens revealed by skin testing. Eur. J. Clin. Invest. 38:260-267.
20. Jutel, M., L. Jaeger, R. Suck, H. Meyer, H. Fiebig, and O. Cromwell. 2005. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol. 116:608-613.
21. Ball, T., B. Linhart, K. Sonneck, K. Blatt, H. Herrmann, P. Valent, A. Stoecklinger, C. Lupinek, J. Thalhamer, A. A. Fedorov, et al. 2009. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination. Allergy 64:569-580.
22. Linhart, B., N. Mothes-Luksch, S. Vrtala, M. Kneidinger, P. Valent, and R. Valenta. 2008. A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. Biol. Chem. 389:925-933.
23. Valenta, R., M. Duchene, C. Ebner, P. Valent, C. Sillaber, P. Deviller, F. Ferreira, M. Tejkl, H. Edelmann, D. Kraft, and O. Scheiner. 1992. Profilins constitute a novel family of functional plant pan-allergens. J. Exp. Med. 175:377-385.
24. Verdino, P., and W. Keller. 2004. Circular dichroism analysis of allergens. Methods 32:241-248.
25. Linhart, B., A. Hartl, B. Jahn-Schmid, P. Verdino, W. Keller, M. T. Krauth, P. Valent, F. Horak, U. Wiedermann, J. Thalhamer, et al. 2005. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J. Allergy Clin. Immunol. 115:1010-1016.
26. Hauswirth, A. W., S. Natter, M. Ghannadan, Y. Majlesi, G. H. Schernthaner, W. R. Sperr, H. J. Bühring, R. Valenta, and P. Valent. 2002. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J. Allergy Clin. Immunol. 110:102-109.
27. Campana, R., S. Vrtala, B. Maderegger, P. Jertschin, G. Stegfellner, I. Swoboda, M. Focke-Tejkl, K. Blatt, A. Gieras, D. Zafred, et al. 2010. Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. J. Allergy Clin. Immunol. 126:1024-1031, e1-e8.
28. Flicker, S., B. Linhart, C. Wild, U. Wiedermann, and R. Valenta. 2013. Passive immunization with allergen-specific IgG antibodies for treatment and prevention of allergy. Immunobiology 218:884-891.
29. Linhart, B., M. Narayanan, M. Focke-Tejkl, F. Wrba, S. Vrtala, and R. Valenta. 2014. Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. Clin. Exp. Allergy 44:278-287.
30. Hamelmann, E., J. Schwarze, K. Takeda, A. Oshiba, G. L. Larsen, C. G. Irvin, and E. W. Gelfand. 1997. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am. J. Respir. Crit. Care Med. 156:766-775.
31. Padavattan, S., S. Flicker, T. Schirmer, C. Madritsch, S. Randow, G. Reese, S. Vieths, C. Lupinek, C. Ebner, R. Valenta, and Z. Markovic-Housley. 2009. High-affinity IgE recognition of a conformational epitope of the major respiratory allergen Phl p 2 as revealed by X-ray crystallography. J. Immunol. 182:2141-2151.
32. Linhart, B., B. Jahn-Schmid, P. Verdino, W. Keller, C. Ebner, D. Kraft, and R. Valenta. 2002. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J. 16:1301-1303.
33. Vrtala, S., M. Focke, J. Kopec, P. Verdino, A. Hartl, W. R. Sperr, A. A. Fedorov, T. Ball, S. Almo, P. Valent, et al. 2007. Genetic engineering of the major timothy grass pollen allergen, Phl p 6, to reduce allergenic activity and preserve immunogenicity. J. Immunol. 179:1730-1739.
34. Mothes-Luksch, N., S. Stumvoll, B. Linhart, M. Focke, M. T. Krauth, A. Hauswirth, P. Valent, P. Verdino, T. Pavkov, W. Keller, et al. 2008. Disruption of allergenic activity of the major grass pollen allergen Phl p 2 by reassembly as a mosaic protein. J. Immunol. 181:4864-4873.
35. Valenta, R., and V. Niederberger. 2007. Recombinant allergens for immunotherapy. J. Allergy Clin. Immunol. 119:826-830.
36. Worm, M., H. H. Lee, J. Kleine-Tebbe, R. P. Hafner, P. Laidler, D. Healey, C. Buhot, A. Verhoef, B. Maillère, A. B. Kay, and M. Larché. 2011. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J. Allergy Clin. Immunol. 127:89-97, e1-e14.
37. Consortium of Food Allergy Research (CoFAR). 2012. Oral immunotherapy for treatment of egg allergy in children. N. Engl. J. Med. 367:233-243.